The European Medicines Agency (EMA) is responsible for coordinating scientific evaluation, supervision, and safety monitoring of medicines in the European Union (EU). The EMA’s Health Threats Plan outlines its approach to prepare for and respond to emerging health threats and public health emergencies, including pandemics, biological, chemical, nuclear, radiological, environmental, and unknown hazards.
The plan builds on EU regulations that empower the EMA to support crisis preparedness and management for medicinal products and medical devices. It emphasizes proactive preparedness activities, including monitoring potential health threats through collaborations with the European Centre for Disease Prevention and Control (ECDC), the European Commission, and international bodies like the World Health Organization (WHO) and the U.S. FDA.
Health threats may be classified as emerging, potential public health emergencies, or actual public health emergencies. The EMA continuously monitors outbreaks or incidents with the potential to escalate, initiating scientific and regulatory activities early to mitigate risks. The EMA Emergency Task Force (ETF) plays a central role, providing scientific advice, coordinating clinical trial support, and advising regulatory committees during such events.
The plan outlines the roles and responsibilities of different EMA entities, including the Crisis Preparedness and Response Steering Group that provides strategic oversight and the Therapeutic Response Group that manages tactical scientific coordination. These groups engage closely with EU member states, international health partners, and industry stakeholders.
During a public health emergency, the EMA may implement accelerated regulatory procedures to speed approval and availability of critical medicines while maintaining quality, safety, and efficacy standards. This includes rolling reviews, rapid scientific advice, pediatric plan adaptations, and flexible inspection approaches for manufacturing and clinical trials.
Communication is essential throughout all phases: Preparedness, emerging threats, and emergencies. The EMA actively engages patients, healthcare professionals, and the public through designated working parties and transparency measures, ensuring timely, accurate information flow.
Cooperation extends beyond the EU to international partners to harmonize responses to global health threats. The EMA works with organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI) and the International Coalition of Medicines Regulatory Authorities (ICMRA) to coordinate medicinal product development and regulatory actions worldwide.
Following emergencies, the EMA conducts lessons learned exercises to improve future response capabilities. The Health Threats Plan provides an adaptable framework with clearly defined procedures, scientific expertise, and contact points to ensure rapid, coordinated actions that protect public health across the EU.
Learn more: Europaema.europa.eu/en/documents/other/ema-health-threats-planen.pdf
